“FDG avid” means a spot on your PET scan is actively soaking up a radioactive sugar tracer called fluorodeoxyglucose, or FDG. The brighter or “hotter” an area appears on the scan, the more aggressively cells there are consuming glucose. Because many cancers are hungry for sugar, doctors use FDG avidity as a signal that something metabolically unusual is happening in that tissue. But avidity alone is not a diagnosis, and understanding what drives it, what fakes it, and what escapes it makes the difference between reading your scan report with clarity and reading it with unnecessary panic.
Why Cancer Cells Gobble Up Glucose
Nearly a century ago, researchers noticed that cancer cells burn through glucose at a remarkably high rate compared to normal cells, churning out large amounts of lactate even when oxygen is available.1PubMed Central. The Warburg effect: 80 years on This metabolic quirk, known as the Warburg effect, is the biological foundation of every FDG PET scan. FDG is a glucose look-alike tagged with a tiny amount of radioactive fluorine-18. Cells pull it inside through the same glucose transporters they use for real sugar, but once FDG gets phosphorylated it cannot be broken down further. It just sits there, trapped, emitting a signal the scanner detects. Tumors with lots of glucose transporter proteins on their surfaces and high levels of the enzyme hexokinase II tend to accumulate more FDG, which is why they glow on the image.2PubMed. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II The development of FDG-PET itself helped reignite scientific interest in Warburg’s original observation, essentially proving his point in living patients decades after it was first described in a lab.3Endocrine-Related Cancer. 100 years of the Warburg effect: a historical perspective – Section: The 2000s – rediscovery of the Warburg hypothesis
How Avidity Gets a Number
Radiologists do not simply eyeball whether a spot looks bright. They assign it a standardized uptake value, or SUV, which compares how much tracer a particular area absorbed relative to the average distribution in your body. An SUV of 1.0 means a region is taking up tracer at a rate you would expect if the FDG were spread evenly everywhere. Most malignant tumors score well above that, often in the range of 5 to 15 or higher, though there is no single cutoff that separates cancer from everything else.
In theory, SUV strips away differences in body size and the amount of tracer injected, making results comparable from one patient to another. In practice, several technical factors introduce noise: the time between injection and scanning, how the scanner reconstructs the image, and the patient’s blood sugar level can all shift the number.4PubMed Central. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy That is why your oncologist reads SUV in context rather than treating it as an absolute verdict. A lesion with an SUV of 3 might be deeply suspicious in the lung but totally unremarkable in the tonsils.
When FDG Avidity Does Not Mean Cancer
One of the most common sources of anxiety after a PET scan is discovering that something lit up. But FDG is not a cancer-specific tracer. Any cell that is burning through glucose faster than its neighbors will grab the tracer, and activated immune cells are especially greedy. Macrophages swarming a site of infection or inflammation can produce uptake that looks just like a tumor.5PubMed Central. FDG-PET/CT pitfalls in oncological head and neck imaging – Section: Inflammation and infection Increased FDG uptake shows up routinely at sites of infection, around catheters, in areas of healing fracture, and in active atherosclerotic plaques in blood vessel walls.
A study cataloging benign FDG-avid findings found that roughly three-quarters were caused by inflammatory processes, with smaller contributions from benign tumors, hematomas, fractures, and fat necrosis.6PubMed. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence Post-surgical inflammation, recent dental work, a granuloma from a foreign body, or even an enthusiastic immune response to a vaccine can all create false-positive spots on a scan.7PubMed. False-positive FDG PET uptake–the role of PET/CT That is one reason PET scans are almost always combined with CT: the anatomical detail from the CT helps the radiologist figure out whether a hot spot sits inside a lymph node, a healing wound, or something else entirely.
In settings where the clinical suspicion of cancer was already high and biopsy was performed, one study found the positive predictive value of FDG-PET/CT for malignancy was about 99%.8PubMed Central. Clinical and FDG-PET/CT Suspicion of Malignant Disease: Is Biopsy Confirmation Still Necessary? – Section: 3.5. PPV of FDG-PET/CT for Malignancy But that number reflects a highly selected group of patients who already had strong clinical reasons to suspect cancer. In an average person being screened or followed after treatment, a single avid spot is far less certain to be malignant. Context matters enormously.
Normal Tissues That Naturally Light Up
Your body has several organs that are always metabolically active and will show FDG uptake on every scan. The brain’s gray matter and the heart are the standout examples: they consume glucose constantly and tend to show the highest tracer accumulation.9PubMed Central. Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients The tonsils, liver, and spleen also routinely show visible uptake in both sexes.10PubMed. Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging The gut can be unpredictable too: smooth-muscle activity and the lymphoid tissue lining the intestines sometimes produce patchy uptake that has nothing to do with disease.
Radiologists are trained to recognize these normal patterns, so they will not mistake your brain lighting up for a metastasis. The challenge arises when a normal variant happens to overlap with a suspicious region. Tonsillar uptake, for instance, is expected, but asymmetric tonsillar uptake might warrant a closer look. This is another area where the combined CT image earns its keep, helping distinguish normal anatomy from something unexpected.
Cancers That Stay Dark
If FDG avidity were a perfect cancer detector, oncology would be simpler. It is not. Certain tumor types have low or even absent FDG uptake, which can lead to a dangerous false sense of reassurance. Well-differentiated tumors, slow-growing cancers, and some specific histologic subtypes are known offenders. Prostate cancer, many neuroendocrine tumors, well-differentiated hepatocellular carcinoma, carcinoid tumors, clear cell renal cell carcinoma, and some subtypes of gastric cancer all fall into this low-avidity category.11PubMed Central. Malignancies with Low Fluorodeoxyglucose Uptake at PET/CT: Pitfalls and Prognostic Importance
Small tumors can also escape detection simply because the scanner cannot resolve them well enough. A lesion under about a centimeter may get averaged together with the surrounding normal tissue, diluting the signal so that even a metabolically active spot appears faint. This partial volume effect is a fundamental limitation of the technology, not a failure of the tracer.
There is an interesting flip side: when a typically low-avidity cancer suddenly shows strong FDG uptake, it can signal that the tumor has become more aggressive or poorly differentiated. Radiologists sometimes use this shift in avidity as an indirect clue about tumor biology, even before a biopsy confirms the change.
How Your Blood Sugar Changes the Picture
Because FDG competes with real glucose for entry into cells, your blood sugar level at the time of the scan matters. High blood glucose floods the transporters with regular sugar, leaving less room for the tracer to get inside. A large meta-analysis pooling data from over 20,000 individual measurements found that elevated blood glucose was linked to lower SUV readings in the brain and muscle but higher readings in the liver and blood pool. Tumor SUV only dropped significantly when blood glucose exceeded about 200 mg/dL.12PubMed. Effect of blood glucose level on standardized uptake value (SUV) in (18)F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements
The brain is especially sensitive. One analysis of over 5,600 patients found that even mildly elevated glucose (110–159 mg/dL) reduced brain cortex SUV by about 23%, with the drop steepening as glucose climbed higher.13Scientific Reports. Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients For oncology imaging, the practical worry is a false-negative result: a tumor that is genuinely there but does not accumulate enough tracer to be spotted. Research comparing patients with high blood sugar to those with normal levels found that hyperglycemia did affect cancer detection rates, though diabetes itself did not reach statistical significance as an independent risk factor.14Journal of Nuclear Medicine. Do Hyperglycemia and Diabetes Affect the Incidence of False-Negative 18F-FDG PET/CT Studies in Patients Evaluated for Infection or Inflammation and Cancer? A Comparative Analysis
This is why imaging centers insist on checking your glucose before injecting the tracer. Most facilities aim for a reading below 150–200 mg/dL and will reschedule if yours is too high. If you have diabetes, you will typically receive specific instructions about managing your insulin and medication timing before the scan.
Getting Ready for the Scan
Patient preparation goes beyond just skipping breakfast. You will generally be told to fast for at least four to six hours before the scan, avoid strenuous exercise the day before, and stay warm and relaxed during the uptake period after the injection. Exercise activates muscles and increases their glucose demand, which pulls tracer away from the areas your doctors actually want to see. Even shivering from a cold waiting room can light up the muscles of your neck and shoulders, potentially obscuring nearby lymph nodes.15Journal of Nuclear Medicine Technology. 18F-FDG PET and PET/CT Patient Preparation: A Review of the Literature
For cardiac imaging, preparation is more involved because the goal is often to suppress the heart’s normal glucose metabolism so that only abnormal inflammatory uptake remains visible. Protocols typically call for a high-fat, no-carbohydrate diet for at least two meals before the scan, followed by a fast.16PubMed Central. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation This dietary manipulation shifts the heart’s fuel preference from glucose to fatty acids, quieting the normal myocardial signal so that any remaining FDG uptake stands out as abnormal.
Using Avidity to Track Treatment Response
One of the most powerful uses of FDG PET is watching how a tumor’s metabolism changes during treatment. A tumor that was intensely avid before chemotherapy and becomes faint afterward is showing a metabolic response, often weeks before the mass actually shrinks on a standard CT scan. Doctors increasingly rely on changes in SUV to make treatment decisions: continue the current regimen, switch to something else, or declare remission. Standardized criteria such as PERCIST (PET Response Criteria in Solid Tumors) formalize this by defining thresholds for metabolic response based on percentage changes in SUV.
Lymphomas are the classic success story here. After a few cycles of chemotherapy, an FDG PET scan can reveal whether any metabolically active disease remains, guiding decisions about whether to proceed with more aggressive treatment or step down. In many solid tumors, the same logic applies: a tumor that stops being avid is, broadly speaking, no longer consuming fuel the way it did, and that is a good sign.
The Post-Radiation Gray Zone
Following radiation therapy, interpreting FDG avidity becomes tricky. Radiation causes inflammation and tissue repair, both of which draw in immune cells that gobble glucose. A scan done too soon after radiation can show avid areas that look alarming but are actually healing tissue, not residual cancer. The general consensus is to wait at least 12 weeks after completing radiation before scanning for response, in order to minimize false-positive findings.17PubMed. Response Evaluation Following Radiation Therapy With (18)F-FDG PET/CT: Common Variants of Radiation-Induced Changes and Potential Pitfalls
Even beyond that window, late radiation effects can develop months or years later and mimic recurrent disease on imaging. Radiation pneumonitis in the lung, for example, can produce a hazy, avid patch that looks suspicious. Radiologists rely on the pattern of uptake, the clinical timeline, and comparison with prior scans to distinguish post-treatment changes from true recurrence. If doubt remains, biopsy or serial imaging at short intervals usually settles the question.
Technical Artifacts That Can Mislead
The physics of PET/CT scanning introduces its own category of false signals. Because the CT portion is used to correct for how much the body absorbs the PET signal (a process called attenuation correction), errors in the CT data can create artifacts on the PET image. Dense materials like metal implants, hip replacements, and dental hardware can overcorrect the signal, making nearby tissue appear falsely avid.18PubMed Central. PET/CT artifacts
Patient motion between the PET and CT acquisitions is another culprit. If you shift position even slightly, the two datasets no longer line up perfectly, which can place tracer activity in the wrong anatomical spot or create spurious hot and cold areas. Breathing motion is especially problematic near the diaphragm, where the liver and lower lung fields move with each breath.19Frontiers in Nuclear Medicine. F-18 FDG PET/CT Imaging in Normal Variants, Pitfalls and Artifacts in the Abdomen and Pelvis – Section: Artifacts Contrast agents swallowed or injected for the CT can also throw off the attenuation correction, though most modern protocols account for this. Experienced radiologists recognize these patterns and adjust their reads accordingly, but they are worth knowing about if you are comparing scan reports over time and notice inconsistencies.
When FDG Is Not the Right Tracer
For certain cancers, FDG simply is not the best tool. Prostate cancer is the textbook example: most prostate tumors have modest glucose metabolism and do not light up reliably on an FDG scan. This limitation drove the development of alternative PET tracers targeting different molecular pathways.20PubMed Central. Non-FDG PET/CT in Diagnostic Oncology: a pictorial review PSMA-targeted tracers, for instance, bind to a protein expressed on the surface of prostate cancer cells and have transformed how the disease is staged and monitored. Gallium-68 DOTATATE targets somatostatin receptors on neuroendocrine tumors, which are another class of cancers that FDG often misses.
In some complex cases, doctors order scans with multiple different tracers to build a fuller picture. A case report of metastatic poorly differentiated thyroid cancer illustrated this approach: the patient’s metastases lit up unevenly across FDG, DOTATATE, and PSMA tracers, showing that different metastatic deposits had different biological characteristics.21PubMed. Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT That kind of heterogeneity is clinically important because it can open doors to targeted therapies, such as peptide receptor radionuclide therapy using DOTATATE, that FDG PET alone would never have suggested.
The expanding menu of PET tracers is steadily filling the gaps that FDG leaves. Amino acid tracers are used for brain tumors, where the brain’s own intense glucose metabolism makes FDG less useful. Choline-based tracers serve certain liver and prostate applications. Each tracer answers a different biological question, and none of them makes FDG obsolete. FDG remains the workhorse for most solid tumors and lymphomas precisely because the Warburg effect is so widespread across cancer types. But if your report mentions that a lesion is “non-FDG-avid,” it does not necessarily mean it is benign. It may just mean a different tracer would tell the story more clearly.